-
Mashup Score: 10Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation - PubMed - 3 year(s) ago
Ibrutinib increases the risk of atrial fibrillation, bleeding, and hypertension compared with non-BTKI therapies. The evidence to support an association between ibrutinib and other cardiovascular complications including ventricular tachyarrhythmias or cardiomyopathy is limited. Ibrutinib metabolism …
Source: PubMedCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia - 3 year(s) ago
The Oncologist is committed to helping physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries on important developments.
Source: The OncologistCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia #ChronicLymphocyticLeukemia #CLL #Acalabrutinib #EuropeanMedicinesAgency #EMA https://t.co/9B3eVgd6Bn https://t.co/hhTEbWuaOk
-
-
Mashup Score: 0JNCCN 360 - CLL - ASCO 2021: Phase III Noninferiority Trial of Acalabrutinib Versus Ibrutinib in CLL - 3 year(s) ago
By: Julia Fiederlein Posted: Tuesday, June 8, 2021 In a phase III open-label, randomized, noninferiority trial, acalabrutinib demonstrated noninferior progression-free survival versus ibrutinib in patients with chronic lymphocytic leukemia (CLL). The results, which were presented by John C. Byrd, MD, of The Ohio State University Wexner Medical Center, Columbus, and…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ASCO21: Phase III noninferiority trial of #acalabrutinib versus #ibrutinib in #CLL: https://t.co/tTpLGNa0qM #leusm #CLLsm #JNCCN360 https://t.co/Hmge8s0tUX
-
-
Mashup Score: 16Meeting Library | Meeting Library - 3 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2021 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Big #CLL news ELEVATE RR results @ASCO abstract #acalabrutinib non-inferior PFS vs #ibrutinib AEs led to Rx d/c 14.7% Acala vs 21.3% IBR. Cardiac, HTN, bleeding ⬇️ with Acala Acala ⬇️ cardiotox and ⬇️ d/c due to AEs vs IBR #CLL https://t.co/BjsjAndWj5 https://t.co/QyXFTXTGf7
-
-
Mashup Score: 0Alexey Danilov, MD, PhD, Discusses the Use of Acalabrutinib for the Treatment of CLL, SLL, and MCL - 3 year(s) ago
In this video, Dr Danilov discusses the use of acalabrutinib as a treatment option for patients with CLL, SLL, and MCL.
Source: Oncology Leanring NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this video, Dr Danilov, @OHSUNews, discusses the use of #acalabrutinib, (@CalquenceHCP) as a treatment option for #patients with CLL, SLL, and MCL. Watch Here: https://t.co/UULj3g798S #MedEd #MedTwitter #Healthcare https://t.co/0FHgk0h1V1
-
-
Mashup Score: 0Tara Graff, DO, Talks About Acalabrutinib and How the CLL Treatment Landscape has Evolved - 3 year(s) ago
In this video, Dr Graff talks about how the treatment landscape for CLL has evolved in recent years, especially with the introduction of acalabrutinib.
Source: Oncology Leanring NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this video interview, Dr Graff, @MercyOneDSM, discusses the evolving treatment landscape for #CLL in recent years, especially with the introduction of #acalabrutinib (Calquence; AstraZeneca). Watch Here: https://t.co/tDq0yoIVV7 https://t.co/0zw9GEAp1W
-
-
Mashup Score: 0Dr. Bhat on the Rationale to Evaluate Acalabrutinib in CLL - 3 year(s) ago
Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@SeemaAliBhat1 of @OSUCCC_James discusses the rationale to evaluate #acalabrutinib in chronic lymphocytic leukemia #CLL https://t.co/rTGycOO6dq https://t.co/LtNBss74zI
-
-
Mashup Score: 0
By: Joseph Fanelli Posted: Monday, October 26, 2020 According to findings presented in Clinical Therapeutics, patients with chronic lymphocytic leukemia (CLL) experienced favorable progression-free survival and overall survival outcomes when treated with Bruton’s tyrosine kinase inhibitor acalabrutinib…
Source: jnccn360.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Comparing front-line treatments in #CLL with a focus on #acalabrutinib: https://t.co/WWAyD5F02a #leusm #JNCCN360 https://t.co/ZwCoHJ5Kfg
-
-
Mashup Score: 0Dr. Bhat on the Rationale to Evaluate Acalabrutinib in CLL - 4 year(s) ago
Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@SeemaAliBhat1, of @OSUCCC_James, discusses the rationale to evaluate #acalabrutinib in chronic lymphocytic leukemia #CLL https://t.co/rTGycOO6dq https://t.co/wEt4geb7DN
-
-
Mashup Score: 2Dr. Bhat on the Rationale to Evaluate Acalabrutinib in CLL - 4 year(s) ago
Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@SeemaAliBhat1, of @OSUCCC_James, discusses the rationale to evaluate #acalabrutinib in chronic lymphocytic leukemia #CLL https://t.co/rTGycOO6dq https://t.co/pmOLtHoc4O
-
RT @DarrylLeong: Bruton's tyrosine kinase Inhibitors and Cardiotoxicity https://t.co/0mmcFgkbsj @avirupguha the #acalabrutinib vs. #ibrutin…